MV140

From WikiProjectMed
Jump to navigation Jump to search
MV140
Names
Trade namesUromune[1]
Clinical data
Main usesPrevention of recurrent urinary tract infections[2]

MV140, sold under the brand name Uromune, is a vaccine used to prevent recurrent urinary tract infections (UTIs).[1][2] It decreases the risk of UTIs by about 60%.[1][3] It appears to be more effective than preventative antibiotics.[4] It is taken as a spray under the tongue.[4]

There does not appear to be significant side effects.[5] Side effects may include vaginal yeast infections.[6] It is made from dead bacteria which commonly cause urinary tract infections; specifically Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis.[7]

MV140 was approved for medical use in Spain in 2010.[1] As of 2020 it is available in a further 25 countries including the United Kingdom, New Zealand, and a number of European countries.[4] It is in the approval process in Canada as of 2023.[1] It is not available in the United States as of 2023.[2] In New Zealand it costs about NZ$360 for three months as of 2023.[8]

Medical use

It may be used in those with recurrent UTIs.[2] Long term usefulness is unclear as of 2023.[2]

Dosage

It is used once a day for three months.[4] Its flavour is of pineapple.[2]

Mechanism of action

It is made using equal amounts of killed bacteria; E.coli, Proteus vulgaris, Klebsiella pneumoniae, and Enterococcus faecalis.[9]

Society and culture

They are not available in the United States or Canada as of 2023.[2] As of 2023, it is available through certain access programs in Australia, Netherlands, New Zealand, Norway, Spain, Sweden, and the United Kingdom.[9] In the United Kingdom, they are not covered by the NHS as of 2023.[2]

Names

Uromune is the brand name for MV140.[1] Brand names of other vaccines for recurrent UTIs include Uro vaxom and Uro Vac.[2][9]

History

It was developed and made in Spain, where it has been marketed since 2010.[9][10]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Sublingual vaccine for urinary tract infections is awaiting approval by Health Canada". CTVNews. 7 March 2023. Archived from the original on 8 March 2023. Retrieved 9 March 2023.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Vaccines". Chronic UTI Info. Archived from the original on 26 March 2023. Retrieved 27 July 2023.
  3. ↑ Lorenzo-Gómez, María-Fernanda; Foley, Stephen; Nickel, J. Curtis; García-Cenador, María-Begoña; Padilla-Fernández, Barbara-Yolanda; González-Casado, Ignacio; Martínez-Huélamo, Misericordia; Yang, Bob; Blick, Christopher; Ferreira, Francini; Caballero, Raquel; Saz-Leal, Paula; Casanovas, Miguel (22 March 2022). "Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections". NEJM Evidence. 1 (4). doi:10.1056/EVIDoa2100018.
  4. ↑ 4.0 4.1 4.2 4.3 Nickel, JC; Saz-Leal, P; Doiron, RC (August 2020). "Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future". Canadian Urological Association journal / Journal de l'Association des urologues du Canada. 14 (8): 281–287. doi:10.5489/cuaj.6690. PMID 33626320.
  5. ↑ Cardozo, Linda; Staskin, David (2023). Textbook of Female Urology and Urogynecology: Clinical Perspectives (5th ed.). CRC Press. p. 1560. ISBN 978-1-000-63122-7. Archived from the original on 2023-07-30. Retrieved 2023-07-27.
  6. ↑ Swatesutipun, Valeerat (March 2023). "Can recurrent UTIs in women be cured? Review article". Continence Reports. 5: 100021. doi:10.1016/j.contre.2023.100021.
  7. ↑ Osborne, Jill (19 February 2022). "Uromune Vaccine To Prevent UTI Showing Remarkable Success". Interstitial Cystitis Network. Archived from the original on 3 June 2023. Retrieved 23 July 2023.
  8. ↑ "Recurrent Urinary Infection". Recurrent Urinary Infection | Bay Urology. Archived from the original on 24 July 2023. Retrieved 23 July 2023.
  9. ↑ 9.0 9.1 9.2 9.3 Kelmis, Caroline; Stephan, Katarina; Varadhan, Ajay; Brown, Jeffrey B.; Preuss, Charles (2023). "Recent developments in the treatment of bacterial urinary tract infections". In Shegokar, Ranjita; Pathak, Yashwant (eds.). Infectious Diseases Drug Delivery Systems. Sitzerland: Springer. p. 396. ISBN 978-3-031-20521-7. Archived from the original on 2023-07-30. Retrieved 2023-07-27.
  10. ↑ Sevilla, Christobel Ramirez; Gomez Lanza, Esther; Manzanera, Juan Llopis; Martin, Juan Antonio Romero; Sanz, Miguel Angel Barranco (2022). "27. Recurrent urinary tract infection". In Dökmeci, Fulya; Rizk, Diaa E. E. (eds.). Insights Into Incontinence and the Pelvic Floor. Springer. p. 211. ISBN 978-3-030-94174-1. Archived from the original on 2023-07-30. Retrieved 2023-07-27.
Retrieved from "https://mdwiki.org/w/index.php?title=MV140&oldid=1406871"